BioNTech stock is trading after a difficult five year stretch, with the share price well below where it was, while valuation checks suggest the stock is not a clear bargain at current levels.

• BioNTech shareholders have seen the stock decline 72.5% over the last five years, which raises the question of whether the current price still embeds expectations that have not been met.
• For a company built around high cost research and development and a concentrated product portfolio, future cash flows can benefit if new treatments scale successfully, but they are also exposed if clinical or commercial progress slows.
• On Simply Wall St's broader checks, BioNTech screens as expensive overall, with only 1 out of 6 valuation tests suggesting the stock is on the cheap side.

The issue now is whether BioNTech's current price fairly reflects this balance of long term potential and ongoing risks, or if the stock appears too richly valued after such a large drawdown.

Find out why BioNTech's -22.5% return over the last year is lagging behind its peers.

Has BioNTech Run Too Far on Sales?

P/S is a useful lens for BioNTech because revenue can be more stable than earnings during heavy research and development investment cycles. BioNTech currently trades on a P/S of 7.1x, compared with an average of 10.8x for the wider biotechs industry and a peer group average of 6.0x.

Simply Wall St’s fair P/S estimate for BioNTech is 5.3x, which reflects the company’s specific mix of margins, risk profile and market position rather than just the raw industry average. Against that benchmark, the stock is priced at a premium, suggesting the market is assigning a higher value to each dollar of sales than this tailored yardstick would support.

On this P/S measure, BioNTech stock screens as overvalued relative to what the model suggests would be a more grounded sales multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The BioNTech Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take BioNTech's valuation puzzle a step further by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price. They sit on the company's Community page. Each Narrative links its number to a specific view of where BioNTech's growth, profitability and risks could move next, giving you something concrete to revisit as fresh information comes through.

The community is split on BioNTech, with one camp focused on oncology upside and another zeroed in on vaccine and trial risk.

Bull case: 28% undervalued

"Robust pipeline expansion in oncology, with multiple late-stage (Phase II/III) clinical trials for BNT327 and mRNA cancer immunotherapies across high-prevalence cancers (lung and breast), positions BioNTech to launch multiple new products, driving significant top-line revenue growth and enhancing earnings visibility over the next several years…"

Read the full Bull Case to see why BioNTech could be undervalued

Bear case: 9% overvalued

"Falling COVID-19 vaccine demand in core markets, including ongoing declines in U.S. vaccination rates and increased vaccine hesitancy globally, is expected to materially reduce long-term revenue from BioNTech's main commercial franchise as public adoption rates stagnate or deteriorate further…"

Read the full Bear Case to see why BioNTech could be overvalued

Do you think there's more to the story for BioNTech? Head over to our Community to see what others are saying!

The Bottom Line

For BioNTech, the current set up points to a stock that still screens as overvalued on sales based measures, even after a difficult five year stretch. The broader valuation checks look weak overall, so any bullish view is leaning heavily on the upside from the pipeline rather than support from current multiples.

The crux from here is whether BioNTech can convert its oncology and broader research pipeline into durable revenue that justifies a richer P/S than peers. If that traction is slower or more uneven than optimists expect, today’s premium could prove hard to defend.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.